[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:amyotrophic-lateral-sclerosis":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":308,"states":313},"Amyotrophic Lateral Sclerosis",99,79,[8,16,22,29,35,42,48,54,60,67,74,81,87,93,98,104,110,116,122,128,134,140,146,152,158,164,170,176,181,187,192,198,204,210,216,222,228,234,240,245,251,257,263,269,275,281,286,291,296,302],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05407324","Dazucorilant in Patients With Amyotrophic Lateral Sclerosis",[12],"Phase 2","RECRUITING","2026-08-26T02:16:44.178623Z","2026-07-05T05:32:16.799228Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07295990","Tongue-strengthening Exercises in People With ALS.",[],"2026-08-26T02:17:17.791881Z","2026-05-13T02:55:06.685180Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06656702","Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis",[26],"Early Phase 1","2026-08-26T02:16:17.877565Z","2026-05-05T02:47:14.265433Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07187388","Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.",[],"2026-08-26T02:18:35.425468Z","2026-05-05T02:43:29.676345Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT07322003","Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS",[39],"Phase 3","2026-08-26T02:15:02.712396Z","2026-05-05T02:43:29.494663Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT07294144","Tofersen in Non-SOD1 ALS",[12],"2026-08-26T02:17:42.501124Z","2026-05-05T02:43:29.202545Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07161999","Study of COYA 302 for the Treatment of ALS",[12],"2026-08-26T02:17:01.714035Z","2026-05-05T02:43:29.153203Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05913882","Combined Respiratory Training in Persons With ALS",[],"2026-08-26T02:18:24.494016Z","2026-05-05T02:43:29.040114Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT04220190","RAPA-501 Therapy for ALS",[64],"Phase 2\u002FPhase 3","2026-08-26T02:18:43.501109Z","2026-05-05T02:43:28.869673Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":72,"content_modified":73},"NCT06665165","AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis",[71],"Phase 1","2026-08-26T02:17:05.997056Z","2026-05-05T02:43:28.711590Z",{"nct_id":75,"title":76,"phases":77,"status":13,"updated_at":79,"content_modified":80},"NCT07017946","Intestinal Microbiome Transplant in ALS",[78],"Phase 1\u002FPhase 2","2026-08-26T02:17:39.048487Z","2026-05-05T02:43:28.509387Z",{"nct_id":82,"title":83,"phases":84,"status":13,"updated_at":85,"content_modified":86},"NCT06649955","Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study",[],"2026-08-26T02:17:06.985283Z","2026-05-05T02:43:28.502471Z",{"nct_id":88,"title":89,"phases":90,"status":13,"updated_at":91,"content_modified":92},"NCT03127267","Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients",[39],"2026-08-26T02:18:51.009190Z","2026-05-05T02:43:28.483351Z",{"nct_id":94,"title":95,"phases":96,"status":13,"updated_at":40,"content_modified":97},"NCT07142291","PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS",[12],"2026-05-05T02:43:28.185063Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT07290062","A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)",[71],"2026-08-26T02:18:36.226508Z","2026-05-05T02:43:27.494050Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT07071935","A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)",[12],"2026-08-26T02:16:57.705506Z","2026-05-05T02:43:27.485942Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT07287397","Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS",[78],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:27.311622Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT06527222","A Study of Ranolazine in ALS",[12],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:27.250679Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT07221240","Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis",[71],"2026-08-26T02:16:20.336282Z","2026-05-05T02:35:31.919621Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT04244630","Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial",[12],"2026-08-26T02:18:49.989941Z","2026-04-29T02:57:57.140742Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT07002034","RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses",[12],"2026-08-26T02:17:32.059863Z","2026-05-05T02:43:28.496200Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT07478172","Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease",[],"2026-08-26T02:18:04.640417Z","2026-04-29T02:57:57.124114Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT02795052","Neurologic Stem Cell Treatment Study",[],"2026-08-26T02:15:11.740957Z","2026-04-29T02:57:57.086071Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT06609213","Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALS",[],"2026-08-26T02:18:47.742071Z","2026-05-05T02:43:29.393264Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT05395624","Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers",[78],"2026-08-26T02:15:34.659160Z","2026-05-05T02:43:28.209644Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT03143374","PET Tau - Neurodegenerative Disease Imaging",[64],"2026-08-26T02:16:03.788292Z","2026-05-05T02:43:28.343973Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":174,"content_modified":175},"NCT04396873","PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease",[71],"2026-08-26T02:18:09.641312Z","2026-05-05T02:43:26.747854Z",{"nct_id":177,"title":178,"phases":179,"status":13,"updated_at":65,"content_modified":180},"NCT07023835","Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis",[12],"2026-07-30T01:46:14.440870Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT07491484","Impact of Physical Functioning on Patient-Reported Outcomes in ALS Patients at TidalHealth",[],"2026-08-26T02:14:59.425132Z","2026-05-13T02:55:06.709795Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":65,"content_modified":191},"NCT07259980","A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)",[],"2026-05-13T02:55:06.681439Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT06885918","ALS Research Collaborative",[],"2026-08-26T02:17:33.807405Z","2026-05-13T02:55:06.588172Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT06735014","Multicenter ALS Imaging Study",[],"2026-08-26T02:16:47.762107Z","2026-05-13T02:55:06.567032Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":208,"content_modified":209},"NCT06581861","PREVENT ALL ALS Study",[],"2026-08-26T02:15:25.633039Z","2026-05-13T02:55:06.553693Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":214,"content_modified":215},"NCT06578195","ASSESS ALL ALS Study",[],"2026-08-26T02:15:52.238965Z","2026-05-13T02:55:06.512802Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":220,"content_modified":221},"NCT06491732","EIM Via the Myolex mScan as an ALS Biomarker",[],"2026-08-26T02:19:26.493949Z","2026-05-13T02:55:06.495128Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":226,"content_modified":227},"NCT05474235","Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders",[],"2026-08-26T02:15:36.077529Z","2026-05-13T02:55:06.350196Z",{"nct_id":229,"title":230,"phases":231,"status":13,"updated_at":232,"content_modified":233},"NCT05137665","Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures",[],"2026-08-26T02:18:14.396999Z","2026-05-13T02:55:06.294766Z",{"nct_id":235,"title":236,"phases":237,"status":13,"updated_at":238,"content_modified":239},"NCT05104710","Intermuscular Coherence as a Biomarker for ALS",[],"2026-08-26T02:16:01.910993Z","2026-05-13T02:55:06.284065Z",{"nct_id":241,"title":242,"phases":243,"status":13,"updated_at":20,"content_modified":244},"NCT05067179","Analysis of Human ALS Tissues and Registry of ALS Patients",[],"2026-05-13T02:55:06.281189Z",{"nct_id":246,"title":247,"phases":248,"status":13,"updated_at":249,"content_modified":250},"NCT04097158","Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone",[],"2026-08-26T02:18:21.216897Z","2026-05-13T02:55:06.233956Z",{"nct_id":252,"title":253,"phases":254,"status":13,"updated_at":255,"content_modified":256},"NCT03865420","Amyotrophic Lateral Sclerosis (ALS) Families Project",[],"2026-08-26T02:18:34.622081Z","2026-05-13T02:55:06.179000Z",{"nct_id":258,"title":259,"phases":260,"status":13,"updated_at":261,"content_modified":262},"NCT02567136","Imaging Biomarkers in ALS",[],"2026-08-26T02:19:08.862440Z","2026-05-13T02:55:06.096975Z",{"nct_id":264,"title":265,"phases":266,"status":13,"updated_at":267,"content_modified":268},"NCT01772602","The National Amyotrophic Lateral Sclerosis Registry",[],"2026-08-26T02:19:08.084946Z","2026-05-13T02:55:06.076795Z",{"nct_id":270,"title":271,"phases":272,"status":13,"updated_at":273,"content_modified":274},"NCT00317616","The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study",[],"2026-08-26T02:15:33.331531Z","2026-05-13T02:55:06.034866Z",{"nct_id":276,"title":277,"phases":278,"status":13,"updated_at":279,"content_modified":280},"NCT00136500","Clinical Research in ALS Study",[],"2026-08-26T02:18:11.042248Z","2026-05-13T02:55:06.031230Z",{"nct_id":282,"title":283,"phases":284,"status":13,"updated_at":150,"content_modified":285},"NCT07233148","Healing ALS Registry Observational Study (HAROS)",[],"2026-05-13T02:55:06.679688Z",{"nct_id":287,"title":288,"phases":289,"status":13,"updated_at":255,"content_modified":290},"NCT05116943","Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders",[],"2026-05-13T02:55:06.284516Z",{"nct_id":292,"title":293,"phases":294,"status":13,"updated_at":255,"content_modified":295},"NCT04721717","AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis",[],"2026-05-13T02:55:06.266961Z",{"nct_id":297,"title":298,"phases":299,"status":13,"updated_at":300,"content_modified":301},"NCT03489278","Clinical Procedures to Support Research in ALS",[],"2026-08-26T02:16:34.792807Z","2026-05-13T02:55:06.126398Z",{"nct_id":303,"title":304,"phases":305,"status":13,"updated_at":306,"content_modified":307},"NCT06539169","FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases",[],"2026-08-26T02:18:44.395098Z","2026-05-13T02:55:06.551987Z",[309],{"biomarker":310,"count":311,"slug":312},"Superoxide Dismutase [Cu-Zn]",4,"superoxide-dismutase-cu-zn",[314,318,322,326,330,334,338,341,344,348,351,355,358,361,365,369,373,376,379,382,386,389,392,396],{"state":315,"count":316,"slug":317},"Florida",34,"florida",{"state":319,"count":320,"slug":321},"California",32,"california",{"state":323,"count":324,"slug":325},"Massachusetts",31,"massachusetts",{"state":327,"count":328,"slug":329},"Pennsylvania",25,"pennsylvania",{"state":331,"count":332,"slug":333},"New York",17,"new-york",{"state":335,"count":336,"slug":337},"Arizona",16,"arizona",{"state":339,"count":336,"slug":340},"Maryland","maryland",{"state":342,"count":336,"slug":343},"Texas","texas",{"state":345,"count":346,"slug":347},"Illinois",13,"illinois",{"state":349,"count":346,"slug":350},"Missouri","missouri",{"state":352,"count":353,"slug":354},"Michigan",11,"michigan",{"state":356,"count":353,"slug":357},"Minnesota","minnesota",{"state":359,"count":353,"slug":360},"North Carolina","north-carolina",{"state":362,"count":363,"slug":364},"Georgia",10,"georgia",{"state":366,"count":367,"slug":368},"Washington",8,"washington",{"state":370,"count":371,"slug":372},"Colorado",7,"colorado",{"state":374,"count":371,"slug":375},"Nebraska","nebraska",{"state":377,"count":371,"slug":378},"Ohio","ohio",{"state":380,"count":371,"slug":381},"Virginia","virginia",{"state":383,"count":384,"slug":385},"Alabama",6,"alabama",{"state":387,"count":384,"slug":388},"Oregon","oregon",{"state":390,"count":384,"slug":391},"Utah","utah",{"state":393,"count":394,"slug":395},"Connecticut",5,"connecticut",{"state":397,"count":394,"slug":398},"District of Columbia","district-of-columbia"]